



## **Imara to Webcast Conference Call of Second Quarter 2020 Financial Results**

August 7, 2020

BOSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Friday, August 14, 2020, at 8:30 a.m. ET to discuss its second quarter 2020 financial results and other business updates.

A live webcast will be available under "Events and Presentations" in the Investors section of the company's website at [imaratx.com](http://imaratx.com). The conference call can be accessed by dialing 1 (833) 519-1307 (U.S. domestic) or +1 (914) 800-3873 (international) and referring to conference ID 9775635. A replay of the webcast will be archived on the Imara website following the presentation.

### **About Imara**

Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit [www.imaratx.com](http://www.imaratx.com).

### **Investor Contact:**

Michael Gray  
617-835-4061  
[mgray@imaratx.com](mailto:mgray@imaratx.com)